Orthocell
Share
Orthocell is a regenerative medicine company that helps surgeons maximise the body’s natural healing potential.
28/05/2026
Orthocell Ltd (ASX:OCC) is proud to be a Gold Sponsor of the Washington University Nerve Course, run by the Global Nerve Foundation (GNF) and WashU Medicine taking place May 29–30 in St Louis.
This two‑day program brings together leading surgeons for advanced training in peripheral nerve repair and reconstruction — an important opportunity to share knowledge that strengthens clinical practice and improves patient outcomes.
We look forward to connecting with colleagues in St Louis.
Learn more about the course here: https://bit.ly/4308ywW
From surgeon education and clinical engagement to investor discussions, our team is preparing for a strong lineup of upcoming industry events across Australia and New Zealand.
📍 Orthocell Nerve Symposium
12 June | Sydney
Now in its fourth year, the Orthocell Nerve Symposium is an advanced educational program designed to provide Orthopaedic and Plastic Surgeons with a broad understanding of peripheral nerve repair and regeneration, including nerve transfer techniques using our collagen-based nerve repair technology, Remplir™. Featuring an international faculty, cadaveric workshops and clinical discussions focused on improving surgical decision-making and patient outcomes.
📍 Plastic Surgery Congress (PSC)
24–25 July | Brisbane
One of Australia’s leading plastic and reconstructive surgery meetings, bringing together surgeons and industry from across the sector. Orthocell’s distribution partner, Device Technologies, will be showcasing Remplir™ throughout the event.
📍 20th Bioshares Biotech Summit
6–7 August | Queenstown, New Zealand
Our executive team will be heading across the Tasman for Bioshares, a key biotech and healthcare investment forum connecting emerging companies with investors and sector stakeholders.
We look forward to seeing you there.
30/04/2026
Orthocell has shared that it has completed the first commercial sales of Remplir™ in the US75 million Canadian market, marking a key milestone in the Company’s global commercialisation strategy for its flagship nerve repair medical device.
The first sales follow regulatory approval from Health Canada for Remplir and distributor appointments in 2H CY25, which currently provide majority national coverage across the Canadian market and position the Company to support surgeon and hospital adoption nationwide.
Orthocell has worked alongside its distributors on initial launch activities, including a KOL-led product roadshow across Canada (Vancouver to Toronto). The program featured Australian orthopaedic surgeon Dr Stuart Kirkham, who presented his clinical experience and use of Orthocell’s Remplir collagen nerve repair device to plastic and orthopaedic peripheral nerve surgeons. This activity supported product education and early engagement, contributing to the first commercial sales.
Following the Canadian launch, Orthocell will continue to work closely with its distributor network to onboard surgeons and establish active accounts, supported by the Company’s existing US-based marketing and medical education teams. This coordinated approach provides clinical engagement, training and operational efficiencies across the U.S. and Canada.
🔗 Read the ASX release: https://bit.ly/4tg90BW
$OCC
Click here to claim your Sponsored Listing.
Category
Contact the business
Website
Address
Building 191 Murdoch University South Street
Perth, WA
6150
Opening Hours
| Monday | 9am - 5pm |
| Tuesday | 9am - 5pm |
| Wednesday | 9am - 5pm |
| Thursday | 9am - 5pm |
| Friday | 9am - 5pm |
